Celogics

Celogics operates as a specialized provider of research-use-only human iPSC-derived cell products, primarily cardiomyocytes, under its Celo.Cells brand. The company leverages proprietary differentiation protocols to produce cells that closely mimic human cardiac electrophysiology for use in 2D, 3D, and organoid systems. Its core value proposition centers on rigorous quality control, validated data, and reliable communication to serve pharmaceutical and academic research clients. Celogics is a private company positioning itself as a trusted partner in the preclinical research tools segment of the cell and gene therapy ecosystem.

Proprietary protocols for differentiating human induced pluripotent stem cells (iPSCs) into functional somatic cell types, with a focus on producing cardiomyocytes that closely mimic human electrophysiology for use in 2D, 3D, and organoid systems.

Celogics competes in the iPSC-derived research products market against large, diversified players like Thermo Fisher Scientific and Fujifilm Cellular Dynamics (FCDI), as well as numerous smaller biotech startups. Differentiation is based on claimed electrophysiological maturity, quality control, and customer service rather than scale.